V
Vor Biopharma
Vor Biopharma is an immuno-oncology company developing novel therapies with broad potential for treating cancer
About Vor Biopharma
Vor Biopharma, accessible at vorbio.com, is a pioneering company in the biopharmaceutical sector, focusing on innovative treatments for blood cancers. The company’s unique approach aims to protect healthy cells while targeting and eliminating cancerous ones. This method has the potential to revolutionize the treatment of blood cancers, particularly Acute Myeloid Leukemia (AML).
Vor Biopharma serves patients suffering from blood cancers, their caregivers, and the broader medical community, including hospitals and oncology centers. The company operates in the highly specialized and competitive biopharmaceutical market, which is driven by the need for advanced and effective cancer treatments.
The business model of Vor Biopharma revolves around research and development (R&D) of novel therapies. They invest heavily in scientific research to develop their proprietary platform and pipeline of treatments. The company generates revenue through partnerships with other pharmaceutical companies, licensing agreements, and eventually, the commercialization of their therapies once they receive regulatory approval.
Vor Biopharma was founded by Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning author, and is supported by a team of world-class leaders and advisors with extensive experience in global biopharma. The company emphasizes collaboration and cross-functional teamwork to advance its mission rapidly.
In summary, Vor Biopharma is dedicated to transforming blood cancer treatment through innovative approaches that protect healthy cells and target cancerous ones. Their business model is centered on R&D, partnerships, and eventual commercialization of their therapies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2021
- Employees
- 117
- Open positions
- 16
- Dealroom signal
- 63.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Mar 2026 | $75M | — | TCGX | ↗ |
| PRIVATE PLACEMENT NON VCOther financing | Dec 2025 | $150M | — | RA Capital Management · Logos Capital · Venrock Healthcare Capital Partners · Forbion Capital Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$34M | — |
| 2025 | $0 | — | −$34M | — |
| 2024 | $0 | — | −$118M | — |
| 2023 | $0 | — | −$123M | — |
| 2022 | $0 | — | −$91M | — |
| 2021 | $0 | — | −$68M | — |
| 2020 | $0 | — | −$43M | — |
Growth signals
Latest recorded traffic for Vor Biopharma is 8.8K monthly website visits, down 48.2% over the last three months. Vor Biopharma's team grew 30% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vor Biopharma in the Boston ecosystem
The Vor Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
5AM Ventures
RA Capital Management
Osage University Partners
Fidelity Investments
Johnson & Johnson
Alexandria Venture Investments
Other known investors7 additional known investors
Caligan Partners
Columbia University
Forbion Capital Partners
Frazier Life Sciences
Logos Capital
TCGX- VPVenrock Healthcare Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vor Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vor Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








